I

    Immuneering Corp (IMRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.99
    +0.00 (+0.00%)

    Market Cap: $322.84M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(14/22)
    Avg Surprise
    +1.99%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.30
    Range$-0.37 - $-0.27
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.32-3.7%
    60d ago$-0.32-3.7%
    30d ago$-0.31-0.6%
    7d ago$-0.32-3.9%
    Current$-0.30
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.29
    Range$-0.48 - $-0.21
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.29---
    Sep 26EST
    		-$-0.30---
    Jun 26
    		$-0.27$-0.26-3.85%Miss+32.5%
    Mar 26
    		$-0.21$-0.35+40.00%Beat+50.0%
    Dec 25
    		$-0.18$-0.31+41.94%Beat+83.2%
    Sep 25
    		$-0.38$-0.39+2.56%Beat+22.4%
    Jun 25
    		$-0.40$-0.40+0.00%Beat+14.9%
    Mar 25
    		$-0.42$-0.58+27.59%Beat+14.3%
    Dec 24
    		$-1.07$-0.45-137.78%Miss-105.8%
    Sep 24
    		$-0.49$-0.55+10.91%Beat-14.0%
    Jun 24
    		$-0.47$-0.53+11.32%Beat-9.3%
    Mar 24
    		$-0.49$-0.50+2.00%Beat+3.9%
    Dec 23
    		$-0.52$-0.47-10.64%Miss-4.0%
    Sep 23
    		$-0.43$-0.49+12.24%Beat+12.2%
    Jun 23
    		$-0.43$-0.53+18.87%Beat+2.3%
    Mar 23
    		$-0.51$-0.56+8.93%Beat-4.1%
    Dec 22
    		$-0.50$-0.58+13.79%Beat-19.0%
    Sep 22
    		$-0.49$-0.48-2.08%Miss-4.3%
    Jun 22
    		$-0.44$-0.52+15.38%Beat+72.7%
    Mar 22
    		$-0.49$-0.44-11.36%Miss+61.1%
    Dec 21
    		$-0.42$-0.39-7.69%Miss+66.6%
    Sep 21
    		$-0.47$-0.62+24.19%Beat+27.3%
    Jun 21
    		$-1.61$-1.44-11.81%Miss-
    Mar 21
    		$-1.26$-1.25-0.80%Miss-
    Dec 20
    		$-1.26$0.00N/AMiss-
    Dec 19
    		$-0.65$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.80EV/EBITDA-1.53x
    Price/FCF-5.66xFCF Yield-17.65%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-52.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio19.47xQuick Ratio19.47x
    Trading Statistics
    Beta0.37Avg Volume648.27K
    52-Week High$10.0852-Week Low$3.86

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.17
    SMA 20$4.96
    SMA 50$4.82
    SMA 200$5.29
    EMA 10$5.09
    EMA 20$4.99
    EMA 50$4.87
    EMA 200$4.94

    MACD

    Line: 0.13Signal: 0.14Hist: -0.01

    ADX

    ADX: 24.3+DI: 25.1-DI: 21.4

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down8.0
    PSAR$5.40

    Bollinger Bands

    Upper Band$5.62
    Lower Band$4.31
    %B Position2621%(Upper)
    Band Width0.52

    RSI (14-Day)

    Neutral
    51.8

    Momentum Oscillators

    Stoch %K54.4
    Stoch %D65.7
    Williams %R-62.9
    ROC (10d)-4.4%
    Momentum-0.23
    CCI (20d)-2.1
    MFI (14d)56.7

    Volatility Measures

    ATR (14d)$0.24(4.8%)
    StdDev (20d)0.33
    Hist Vol49.8%(High)

    Volume Flow

    VWAP$4.95
    OBV8.2M
    AD Line-25.1M
    CMF (20d)0.069

    Volume Metrics

    Avg Vol (20d)655.8K
    Vol Ratio0.9x
    VWMA (20d)$4.94

    Pivot Points

    R3$5.44
    R2$5.33
    R1$5.16
    Pivot Point$5.05
    S1$4.88
    S2$4.77
    S3$4.60

    Advanced Oscillators

    TSI14.19
    Ultimate Osc40.8
    KST118.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$726,326$0$0$0$-94,419,000$0
    Cost of Revenue$0$0$612,729$0$0$0$174,645$0$0$0$185,216$0
    Gross Profit$0$0$-612,729$0$0$0$-174,645$0$0$0$-185,216$0
    Operating Expenses$19.00M$15.34M$13.75M$15.38M$14.76M$15.48M$18.56M$15.27M$14.91M$15.33M$16.30M$13.93M
    R&D$14.00M$10.65M$9.25M$10.87M$10.45M$11.47M$14.86M$11.25M$10.65M$11.20M$11.91M$10.05M
    SG&A$5.00M$4.68M$4.49M$4.51M$4.30M$4.01M$3.69M$4.01M$4.25M$4.12M$4.38M$3.87M
    Operating Income$-19,000,408$-15,335,034$-13,752,717$-15,380,706$-14,757,894$-15,484,652$-18,558,155$-15,273,748$-14,913,748$-15,325,750$-16,301,987$-13,926,338
    Interest Income$1.08M$1.36M$1.86M$415,831$324,013$438,520$415,240$547,072$826,104$804,884$754,143$855,532
    Interest Expense$0$0$0$0$0$0$0$0$0$0$115,774$0
    Income Before Tax$-17,270,427$-13,974,630$-11,891,675$-14,964,875$-14,433,881$-15,046,132$-18,279,942$-14,597,366$-14,079,927$-14,520,866$-16,417,761$-12,595,211
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-17,270,427$-13,460,895$-11,580,010$-14,964,875$-14,433,881$-15,046,132$-18,051,486$-14,597,366$-14,079,927$-14,307,829$-15,083,492$-12,595,211
    EBITDA$-18,840,400$-15,651,038$-13,825,259$-15,294,549$-14,666,051$-15,392,074$-18,520,412$-15,082,312$-14,815,894$-15,389,863$-16,196,492$-13,677,116
    EBIT$-18,353,211$-15,335,034$-13,752,717$-15,380,706$-14,757,894$-15,484,652$-18,558,155$-15,144,438$-14,906,031$-15,325,750$-16,301,987$-13,450,743
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMRX

    News

    This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

    This article highlights three companies that received new "Buy" ratings from Wall Street analysts. Lyell Immunopharma Inc., Immuneering Corp., and Atrium Therapeutics Inc. were initiated with bullish coverage, each receiving a price target significantly above their recent closing prices.

    Sahm•8/7/26•
    Neutral

    BlackRock, Inc. (NYSE: BLK) discloses 6.7% ownership in Immuneering Corp (IMRX)

    BlackRock, Inc. has disclosed a 6.7% ownership stake in Immuneering Corp (IMRX), as reported in a Schedule 13G SEC filing. This position amounts to 4,356,235 shares of Immuneering’s Class A stock as of June 30, 2026. BlackRock holds sole voting power over 4,314,766 shares and sole dispositive power over all 4,356,235 beneficially owned shares.

    Stock Titan•7/28/26•
    Neutral

    Immuneering’s New CFO Gets 650,000-Share Option With $4.78 Exercise Price

    Immuneering Corporation (NASDAQ: IMRX) has granted a 650,000-share option to its new CFO, Andrew Gengos, as an inducement award, with an exercise price of $4.78 per share. This ten-year option, alongside a smaller grant to a non-executive employee, vests over four years and was issued under Nasdaq Rule 5635(c)(4). The grants are part of the company's 2025 Employment Inducement Award Plan and reflect its ongoing focus as a late-stage clinical oncology company.

    Stock Titan•7/18/26•
    Somewhat-Bullish

    Immuneering (IMRX) awards CFO Andrew Gengos 650,000 stock options

    Immuneering Corp (IMRX) has granted its CFO, Andrew Gengos, stock options for 650,000 shares of Class A Common Stock. The exercise price is set at $4.78 per share, and the options are set to expire on July 16, 2036. These options will vest monthly over a four-year period, contingent on Gengos's continued employment.

    Stock Titan•7/17/26•
    Somewhat-Bullish

    Immuneering Corp (IMRX) CFO discloses 225,000 Class A shares

    Immuneering Corp's Chief Financial Officer, Andrew Gengos, has reported direct ownership of 225,000 shares of the company's Class A Common Stock. This disclosure is a Form 3 filing, which is an initial statement of beneficial ownership, and does not indicate any open-market transactions or derivative positions. The filing reflects his equity stake as an officer of Immuneering Corp (IMRX).

    Stock Titan•7/16/26•
    Neutral

    Frequently Asked Questions About IMRX

    Does IMRX pay dividends?
    Immuneering Corp (IMRX) does not currently pay a regular dividend.
    What is IMRX's market cap?
    Immuneering Corp (IMRX) has a market capitalization of $322.84M with a current stock price of $4.99.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In